Portfolio company
ARTV
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This clinical-stage biotechnology company develops natural killer cell therapies for patients with autoimmune diseases and cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Artiva
Artiva Biotherapeutics develops off-the-shelf natural killer cell therapies to treat patients with autoimmune diseases and cancers.
Artiva Biotherapeutics
The company develops allogeneic natural killer cell therapies for patients with autoimmune diseases and cancer.
Nkarta
This biopharmaceutical company develops engineered natural killer cell therapies to treat patients with cancer and autoimmune diseases.
NKIO
This company develops natural killer cell therapies and small molecule medicines to treat solid tumours for patients with cancer and inflammatory diseases.
Arcellx
This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.
Cabaletta Bio
This clinical-stage biotechnology company develops engineered T cell therapies for patients with various autoimmune diseases.
Modulus Therapeutics
This company develops engineered NK-cell therapies for autoimmune disease patients using a generative design and rapid prototyping platform.
Autolus Therapeutics
This company develops programmed T-cell therapies for patients with cancer and autoimmune diseases.